* has severe or critical covid-19 as defined in section 7.2.2. * bedridden (totally confined to bed) * has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis * females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding * receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) * received ivermectin within 1 month prior to the randomization * receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) * history of hypersensitivity to ivermectin or favipiravir or any components of the drugs * receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. * has history of hereditary xanthinuria * has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis * participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening

* has severe or critical covid-19 as defined in section 7.2.2. * bedridden (totally confined to bed) * has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis * females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding * receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) * received ivermectin within 1 month prior to the randomization * receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) * history of hypersensitivity to ivermectin or favipiravir or any components of the drugs * receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. * has history of hereditary xanthinuria * has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis * participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening

has severe or critical covid-19 as defined in section 7.2.2. bedridden (totally confined to bed) has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) received ivermectin within 1 month prior to the randomization receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) history of hypersensitivity to ivermectin or favipiravir or any components of the drugs receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. has history of hereditary xanthinuria has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening

has severe or critical covid-19 as defined in section 7.2.2. bedridden (totally confined to bed) has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) received ivermectin within 1 month prior to the randomization receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) history of hypersensitivity to ivermectin or favipiravir or any components of the drugs receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. has history of hereditary xanthinuria has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening

None

None

has severe or critical covid-19 as defined in section 7.2.2. bedridden (totally confined to bed) has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) received ivermectin within 1 month prior to the randomization receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) history of hypersensitivity to ivermectin or favipiravir or any components of the drugs receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. has history of hereditary xanthinuria has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening

has severe or critical covid-19 as defined in section 7.2.2. bedridden (totally confined to bed) has elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) over 3 times the upper range of normal limits, or history of liver cirrhosis females only: currently pregnant, as determined by positive β-human choriogonadotropin (hcg) test in urine, or breast-feeding receiving other potential drugs for covid-19 treatment prior to randomization including remdesivir, nitazoxanide, chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, famotidine, tocilizumab, baricitinib (except favipiravir) received ivermectin within 1 month prior to the randomization receiving other immunosuppressive or immunomodulatory drugs for the treatment of other conditions (not including topical steroids) history of hypersensitivity to ivermectin or favipiravir or any components of the drugs receiving medications that increase gamma-aminobutyric acid (gaba) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent or inhibit the p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, st. john's wort etc. has history of hereditary xanthinuria has hypouricemia (serum uric acid ≤ 1 mg/dl), uncontrolled gout or history of xanthine urolithiasis participating in other clinical trials or participated in other clinical trials in a period of one month or less than 5 half-lives of the study drug before screening